{
    "ticker": "GTBP",
    "name": "GT Biopharma, Inc.",
    "description": "GT Biopharma, Inc. is a biotechnology company focused on developing innovative immuno-oncology therapies for the treatment of cancer. Founded in 2014, GT Biopharma is dedicated to harnessing the power of the immune system to fight cancer through its proprietary platforms. The company is best known for its innovative TriTAC platform, which is designed to create antibody-like therapeutics that engage T cells to target and kill cancer cells effectively. GT Biopharma's lead product candidate, GTB-3550, is an engineered T cell engager that is currently in clinical trials for various hematological malignancies. The company is committed to advancing its pipeline of therapies through rigorous research and clinical studies, with the goal of providing patients with new and effective treatment options. With a team of experienced scientists and industry veterans, GT Biopharma strives to make significant contributions to the field of cancer immunotherapy and improve patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2014",
    "website": "https://www.gtbiopharma.com",
    "ceo": "Anthony Cataldo",
    "social_media": {
        "twitter": "https://twitter.com/GTBiopharma",
        "linkedin": "https://www.linkedin.com/company/gt-biopharma/"
    },
    "investor_relations": "https://www.gtbiopharma.com/investor-relations",
    "key_executives": [
        {
            "name": "Anthony Cataldo",
            "position": "CEO"
        },
        {
            "name": "David W. Pritchett",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immuno-Oncology Therapies",
            "products": [
                "GTB-3550"
            ]
        }
    ],
    "seo": {
        "meta_title": "GT Biopharma, Inc. | Innovative Immuno-Oncology Solutions",
        "meta_description": "Explore GT Biopharma, Inc., a leader in biopharmaceuticals focused on immuno-oncology therapies for cancer treatment. Learn about our innovative product pipeline and commitment to patient care.",
        "keywords": [
            "GT Biopharma",
            "Immuno-Oncology",
            "Cancer Treatment",
            "Biotechnology",
            "GTB-3550"
        ]
    },
    "faq": [
        {
            "question": "What does GT Biopharma specialize in?",
            "answer": "GT Biopharma specializes in developing innovative immuno-oncology therapies for cancer treatment."
        },
        {
            "question": "Who is the CEO of GT Biopharma?",
            "answer": "Anthony Cataldo is the CEO of GT Biopharma, Inc."
        },
        {
            "question": "Where is GT Biopharma headquartered?",
            "answer": "GT Biopharma is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What is GTB-3550?",
            "answer": "GTB-3550 is GT Biopharma's lead product candidate, designed to target and kill cancer cells through T cell engagement."
        },
        {
            "question": "When was GT Biopharma founded?",
            "answer": "GT Biopharma was founded in 2014."
        }
    ],
    "competitors": [
        "NTRA",
        "CLVS",
        "CRMD",
        "IBIO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}